Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers

Core Insights - Aclarion, Inc. is leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying chronic low back pain locations through its platform, Nociscan [1][3] - The company recently presented at LSI Europe '25, highlighting Nociscan's potential to transform the chronic low back pain market and enhance shareholder value [2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques [3] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3] Technology and Clinical Evidence - Nociscan converts MR spectroscopy signals into objective biomarker data, aiding physicians in creating personalized treatment plans [5] - The ongoing 300-patient CLARITY randomized clinical trial aims to demonstrate that Nociscan-guided surgical decision-making can improve surgical outcomes beyond the current 54% industry success rate, with interim results expected in Q2 2026 [5] Financial Position - Aclarion has recently strengthened its balance sheet, providing the necessary capital to achieve commercial and clinical milestones [5]